Company intelligence / Profile preview
Junshi Biosciences
Shanghai, Shanghai, Chinajunshipharma.com ↗
- Ownership
- Private
- Employees
- ~2300
- Development stage
- Other
01
Overview
Junshi Biosciences has commercialized multiple therapies (notably the PD-1 monoclonal antibody toripalimab, marketed as TUOYI®/LOQTORZI in China and internationally), with over 30 clinical-stage assets spanning oncology, autoimmune, metabolic, neurological, and infectious diseases. Its innovative R&D covers antibodies, small molecules, ADCs, bispecifics, and nucleic acid drugs. Recent clinical success includes FDA approval and US market entry of toripalimab, multiple late-stage oncology trials, and expansion of its product franchise across geographies[4][5][8].
- Therapeutic areas
- OncologyImmunologyInfectious DiseasesMetabolic DisordersNeurology
- Modalities
- Monoclonal antibodySmall moleculeAntibody-drug conjugateBispecific monoclonal antibodyNucleic acid drugPolypeptide drugFusion proteinVaccine
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Coherus BioSciences (US commercialization partner for toripalimab/LOQTORZI)[4]Risen Biosciences (PI3K-α inhibitor development)[6]Anwita Biosciences (IL-21 fusion protein)[6]
Beyond the preview
Go deeper on Junshi Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Junshi Biosciences.